Amarantus BioSciences Receives Grant from Brewer Sports International for Traumatic Brain Injury
November 30 2011 - 9:01AM
Business Wire
Amarantus BioSciences, Inc. (OTCBB:AMBS), a biotechnology
company developing Mesencephalic-Astrocyte-derived Neurotrophic
Factor (MANF), a first-in-class disease–modifying therapeutic
protein, today announced a commitment by Brewer Sports
International (BSI) to fund a pre-clinical study evaluating MANF’s
potential as a treatment for Traumatic Brain Injury (TBI). This
funding will support the collaboration recently announced between
Amarantus and Banyan Biomarkers.
“Concussion management is a serious issue affecting athletes in
a wide variety of sports and other activities, and we are grateful
for this initial contribution from Brewer Sports to test MANF
against this debilitating condition,” said Gerald Commissiong,
President and CEO of Amarantus. “As a former professional athlete,
I have a vested interest in this area of focus for Amarantus and
look forward to reporting on the results in early 2012.”
As a multi-faceted sports management and financial services
firm, Brewer Sports International is focused on providing tailored
solutions to emerging sports and wellness-related companies through
its vast network. BSI’s CEO Jack Brewer played for five years in
the National Football League, retiring in 2007. Many of BSI’s
professional athlete clientele participate in sports where
concussions are prevalent, and the firm maintains a strong desire
to advance research and awareness in the area. The Amarantus study
targeting TBI fits this focus and if the initial study is positive,
Brewer will help Amarantus identify additional funding channels to
support further studies.
“As an ex-NFL player I personally have experienced hundreds of
violent collisions throughout my career and also have several
teammates and friends who suffer the lasting effects of Traumatic
Brain Injury,” said Jack Brewer, CEO of Brewer Sports
International. “This is a passion of mine and BSI is committed to
helping advance TBI research and development. I am hopeful that our
support and this collaboration will help raise awareness and
establish new technology for the treatment of brain injury and
concussions.”
About MANF (Mesencephalic-Astrocyte-derived Neurotrophic
Factor)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a
protein that corrects protein misfolding, one of the major causes
of apoptosis (cell death). This property provides a compelling
rationale for the research and development of MANF-based products
as therapeutics for human disease. The lead MANF product
development effort is centered on a therapy for Parkinson's
disease, currently funded by a research grant from the Michael J.
Fox Foundation for Parkinson’s Research. The Company also owns an
inventory of 88 cell lines referred to as “PhenoGuard Cell Lines.”
MANF was the first therapeutic protein discovered from a PhenoGuard
Cell Line. It is anticipated that additional therapeutic proteins
useful for various therapeutic approaches to the Central Nervous
System (CNS) will be identified from the Company’s inventory of
PhenoGuard Cell Lines.
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a California-based
development-stage biotechnology company founded in January 2008.
The Company has a focus on developing certain biologics surrounding
the intellectual property and proprietary technologies it owns
to treat Parkinson’s disease and other human diseases. The Company
owns the intellectual property rights to a therapeutic protein
known as Mesencephalic-Astrocyte-derived Neurotrophic Factor
("MANF"). For further information please visit
www.amarantus.com.
About Brewer Sports International
Brewer Sports International (BSI) offers a boutique of sports
lending, corporate advisory and entertainment services for
professional athletes, sports agencies, public and private
corporations and various partners including international
organizations, governments and NGOs. Based in Minneapolis, with
offices in New York, Boca Raton and Beijing, BSI was founded by
Jack Brewer, a five-year National Football League (NFL) veteran and
former team captain on three NFL teams. Additionally, BSI has
created a unique financial services platform that is offered to
professional athletes and sports agencies, as well as high net
worth individuals and businesses touching professional sports. BSI
takes pride in building value for its clients through sports and
entertainment. For more information, please visit
www.brewersports.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about the possible benefits of MANF therapeutic applications and/or
advantages presented by Amarantus’ PhenoGuard technology, as well
as statements about expectations, plans and prospects of the
development of Amarantus' new product candidates. These
forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including the risks that the
anticipated benefits of the therapeutic drug candidates or
discovery platforms, as well as the risks, uncertainties and
assumptions relating to the development of Amarantus' new product
candidates, including those identified under "Risk Factors" in
Amarantus' most recently filed Annual Report on Form 10-K and
Quarterly Report on Form 10-Q and in other filings Amarantus
periodically makes with the SEC. Actual results may differ
materially from those contemplated by these forward-looking
statements Amarantus does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this
presentation.
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Sep 2023 to Sep 2024